Biomarin Pharmaceutical Inc (BMRN) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Contact:

Investors:

Media:

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

Three Months Ended September 30,

Nine Months Ended September 30,

2018

2017

% Change

2018

2017

% Change

Total Revenues

$

391.7

$

334.1

17

%

$

1,138.0

$

955.3

19

%

Vimizim Net Product Revenues

123.3

90.3

37

%

368.0

299.3

23

%

Kuvan Net Product Revenues

113.3

105.8

7

%

321.4

300.1

7

%

Naglazyme Net Product Revenues

103.1

72.1

43

%

269.2

238.4

13

%

Aldurazyme Net Product Revenues

27.6

22.4

23

%

117.7

61.7

91

%

Brineura Net Product Revenues

9.9

3.1

219

%

27.7

3.4

715

%

Palynziq Net Product Revenues

4.1

—

n/a

4.1

—

n/a

GAAP Net Loss

$

(12.6

)

$

(12.5

)

$

(73.6

)

$

(65.7

)

GAAP Net Loss per Share - Basic and Diluted

$

(0.07

)

$

(0.07

)

$

(0.42

)

$

(0.38

)

Non-GAAP Income ⁽¹⁾

$

60.7

$

7.8

$

101.8

$

68.7

September 30,

December 31,

2018

2017

Cash, cash equivalents and investments

$

1,648.3

$

1,781.7

(1)

Non-GAAP Income is defined by the Company as reported GAAP Net Income (Loss), excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company’s Non-GAAP financial information and reconciliations to the comparable information reported under Generally Accepted Accounting Principles in the United States (US GAAP).